Interestingly, the use of AMG 510 (a KRAS G12C inhibitor) in pre-clinical models showed a prominent effect on anti-tumor immunity, causing an increase of CD3+, CD8+ T, and dendritic cell infiltration and inducing upregulation of MHC class I complex on tumor cells. Here, CD8A is linked to neoplasm.